Implantable valve prosthesis

Information

  • Patent Grant
  • 9775704
  • Patent Number
    9,775,704
  • Date Filed
    Monday, March 12, 2007
    17 years ago
  • Date Issued
    Tuesday, October 3, 2017
    6 years ago
Abstract
The present invention provides valve prostheses adapted to be initially crimped in a narrow configuration suitable for catheterization through body ducts to a target location and adapted to be deployed by exerting substantially radial forces from within by means of a deployment device to a deployed state in the target location.
Description
FIELD OF THE INVENTION

The present invention relates to implantable devices. More specifically, the present invention relates to heart valve prosthetic devices for cardiac implantation. The present invention may also be utilized in other body cavities, vessels, or ducts.


BACKGROUND OF THE INVENTION

The transport of vital fluids in the human body is largely regulated by valves. Physiological valves are designed to prevent the backflow of bodily fluids, such as blood, lymph, urine, bile, etc., thereby keeping the body's fluid dynamics unidirectional for proper homeostasis. For example, venous valves maintain the upward flow of blood, particularly from the lower extremities, back toward the heart, while lymphatic valves prevent the backflow of lymph within the lymph vessels, particularly those of the limbs.


Because of their common function, valves share certain anatomical features despite variations in relative size. The cardiac valves are among the largest valves in the body with diameters that may exceed 30 mm, while valves of the smaller veins may have diameters no larger than a fraction of a millimeter. Regardless of their size, however, many physiological valves are situated in specialized anatomical structures known as sinuses. Valve sinuses can be described as dilations or bulges in the vessel wall that houses the valve. The geometry of the sinus has a function in the operation and fluid dynamics of the valve. One function is to guide fluid flow so as to create eddy currents that prevent the valve leaflets from adhering to the wall of the vessel at the peak of flow velocity, such as during systole. Another function of the sinus geometry is to generate currents that facilitate the precise closing of the leaflets at the beginning of backflow pressure. The sinus geometry is also important in reducing the stress exerted by differential fluid flow pressure on the valve leaflets or cusps as they open and close.


Thus, for example, the eddy currents occurring within the sinuses of Valsalva in the natural aortic root have been shown to be important in creating smooth, gradual and gentle closure of the aortic valve at the end of systole. Blood is permitted to travel along the curved contour of the sinus and onto the valve leaflets to effect their closure, thereby reducing the pressure that would otherwise be exerted by direct fluid flow onto the valve leaflets. The sinuses of Valsalva also contain the coronary ostia, which are outflow openings of the arteries that feed the heart muscle. When valve sinuses contain such outflow openings, they serve the additional purpose of providing blood flow to such vessels throughout the cardiac cycle.


When valves exhibit abnormal anatomy and function as a result of valve disease or injury, the unidirectional flow of the physiological fluid they are designed to regulate is disrupted, resulting in increased hydrostatic pressure. For example, venous valvular dysfunction leads to blood flowing back and pooling in the lower legs, resulting in pain, swelling and edema, changes in skin color, and skin ulcerations that can be extremely difficult to treat. Lymphatic valve insufficiency can result in lymphedema with tissue fibrosis and gross distention of the affected body part. Cardiac valvular disease may lead to pulmonary hypertension and edema, atrial fibrillation, and right heart failure in the case of mitral and tricuspid valve stenosis; or pulmonary congestion, left ventricular contractile impairment and congestive heart failure in the case of mitral regurgitation and aortic stenosis. Regardless of their etiology, all valvular diseases result in either stenosis, in which the valve does not open properly, impeding fluid flow across it and causing a rise in fluid pressure, or insufficiency/regurgitation, in which the valve does not close properly and the fluid leaks back across the valve, creating backflow. Some valves are afflicted with both stenosis and insufficiency, in which case the valve neither opens fully nor closes completely.


Because of the potential severity of the clinical consequences of valve disease, valve replacement surgery is becoming a widely used medical procedure, described and illustrated in numerous books and articles. When replacement of a valve is necessary, the diseased or abnormal valve is typically cut out and replaced with either a mechanical or tissue valve. A conventional heart valve replacement surgery involves accessing the heart in a patient's thoracic cavity through a longitudinal incision in the chest. For example, a median sternotomy requires cutting through the sternum and forcing the two opposite halves of the rib cage to be spread apart, allowing access to the thoracic cavity and the heart within. The patient is then placed on cardiopulmonary bypass, which involves stopping the heart to permit access to the internal chambers. Such open heart surgery is particularly invasive and involves a lengthy and difficult recovery period. Reducing or eliminating the time a patient spends in surgery is thus a goal of foremost clinical priority.


One strategy for reducing the time spent in surgery is to eliminate or reduce the need for suturing a replacement valve into position. Toward this end, valve assemblies that allow implantation with minimal or no sutures would be greatly advantageous. Attaching a valve such as a tissue valve to a support structure such as a stent may enable a valve assembly that allows implantation with minimal or no sutures. It is important that such valve constructs are configured such that the tissue leaflets or the support valve don't come into contact with the support structure, either during the collapsed or expanded state, or both in order to prevent abrasion. Such contact is capable of contributing undesired stress on the valve leaflet. Moreover, it is advantageous that such support structures are configured to properly support a tissue valve having a scalloped inflow annulus such as that disclosed in the U.S. patent application Ser. No. 09/772,526, issued as U.S. Pat. No. 6,682,559 on Jan. 27, 2004, which is incorporated by reference herein in its entirety.


Accordingly, there is a need for a valve replacement system comprising a collapsible and expandable valve assembly that is capable of being secured into position with minimal or no suturing; facilitating an anatomically optimal position of the valve; maintaining an open pathway for other vessel openings of vessels that may be located in the valvular sinuses; and minimizing or reducing stress to the tissue valve leaflets. The valves of the present invention may comprise a plurality of joined leaflets with a corresponding number of commissural tabs. Generally, however, the desired valve will contain two to four leaflets and commissural tabs. Examples of other suitable valves are disclosed in U.S. patent application Ser. No. 09/772,526, issued as U.S. Pat. No. 6,682,559 on Jan. 27, 2004, Ser. No. 09/853,463, issued as U.S. Pat. No. 6,682,558 on Jan. 27, 2004, Ser. No. 09/924,970, issued as U.S. Pat. No. 6,673,109 on Jan. 6, 2004, Ser. No. 10/121,208, issued as U.S. Pat. No. 6,719,787 on Apr. 13, 2004, Ser. No. 10/122,035, issued as U.S. Pat. No. 6,736,846 on May 18, 2004, Ser. No. 10/153,286, issued as U.S. Pat. No. 6,719,789 on Apr. 13, 2004, and Ser. No. 10/153,290, issued as U.S. Pat. No. 6,718,788 on Apr. 13, 2004, the disclosures of all of which are incorporated by reference in their entirety herein. Likewise, the systems and methods disclosed in U.S. patent application Ser. No. 10/831,770, filed Apr. 23, 2004 which published as US2005/0240200 on Oct. 27, 2005, are fully incorporated by reference herein.


As mentioned above, an open-heart valve replacement is a long tedious procedure. For implantation of a bioprosthetic valve in the aortic position, a surgeon typically opens the aorta and excises the native valve. The surgeon then inserts the prosthetic valve through the opening in the aortic wall and secures the prosthesis at the junction of the aorta and the left ventricle. The inflow annulus of the valve faces the left ventricle and, relative to the surgeon's perspective, may be termed the distal annulus, while the outflow annulus of the valve faces the aorta and may be termed the proximal annulus.


An alternative procedure for approaching the left atrium and the aortic or mitral valve is by intravascular catherization from a femoral vein through the cardiac septum, which separates the right atrium and the left atrium. Yet another alternative for approaching the left atrium and the aortic or mitral valve is by intravascular catherization from a femoral artery up through aortic valve.


Andersen et al. in U.S. Pat. No. 6,582,462, entire contents of which are incorporated herein by reference, discloses a valve prosthesis for implantation in a body channel having an inner wall, the prosthesis comprising a radially collapsible and expandable cylindrical stent, the stent including a cylindrical support means having a cylinder surface; and a collapsible and expandable valve having commissural points, the valve mounted to the stent at the commissural points, wherein the stent and valve are configured to be implanted in the body by way of catheterization. It is one aspect of the present invention to utilize a balloon expandable stent coupled with a tissue valve. An alternative embodiment in the present invention to utilizing a balloon expandable stent is to utilize a self-expandable stent. Yet another alternative embodiment of the present invention to utilizing a balloon expandable stent is to utilize a stent that may be expanded with mechanical means.


Sterman et al. in U.S. Pat. No. 6,283,127, entire contents of which are incorporated herein by reference, discloses a device system and methods facilitating intervention within the heart or great vessels without the need for a median sternotomy or other form of gross thoracotomy, substantially reducing trauma, risk of complication, recovery time, and pain for the patient. Using the device systems and methods of the invention, surgical procedures may be performed through percutaneous penetrations within intercostal spaces of the patient's rib cage, without cutting, removing, or significantly displacing any of the patient's ribs or sternum. The device systems and methods are particularly well adapted for heart valve repair and replacement, facilitating visualization within the patient's thoracic cavity, repair or removal of the patient's natural valve, and, if necessary, attachment of a replacement valve in the natural valve position.


Haluck in U.S. Pat. No. 6,685,724, entire contents of which are incorporated herein by reference, discloses a surgical instrument for use in performing endoscopic procedures having a handle and an elongate tubular member having a proximal end coupled with the handle for being disposed externally of the anatomical cavity and a distal end for being disposed within the anatomical cavity. The distal end further includes a pair of opposed, relatively movable jaws that form a grasping portion operable by manipulation of the handle to releasably grasp a releasable trocar. The releasable trocar has a complementarily shaped shank, a relatively sharp tip and may include a pair of blunt-edge tissue separators that project outwardly from the outer surface of the trocar.


Endoscopic and minimally invasive medical procedures, such as laparoscopy, have become widely accepted for surgery and illness diagnosis. This is due to reduced trauma to the patient and reduced hospitalization time. Other techniques exist for creating a working space within the body cavity. At the beginning of most laparoscopic cases, a small incision is made, followed by a small (about 1 cm) port in the remaining layers of the tissue wall so as to gain access to the cavity.


Hunsberger in U.S. Pat. No. 6,613,063, entire contents of which are incorporated herein by reference, discloses a trocar assembly which includes a shank having a distal end and a proximal end, and a planar piercing blade having two substantially flat faces and a cutting contour, where the piercing blade is integrally attached to the distal end of the shank. The shank tapers inwardly towards the opposed flat faces of the piercing blade.


Further, McFarlane in U.S. Pat. No. 6,478,806, entire contents of which are incorporated herein by reference, discloses a tissue penetrating instrument of the type used in the medical field and which may or may not be embodied in the form of an obturator associated with a trocar assembly, wherein the instrument includes an elongated shaft having a penetrating tip mounted on one end thereof. The penetrating tip includes a base secured to the one end of the shaft and a distal extremity spaced longitudinally outward from the base and formed into an apex which may be defined by a point or other configuration specifically structured to facilitate penetration or puncturing of bodily tissue.


Spenser et al. disclose in U.S. patent application Ser. No. 09/975,750, issued as U.S. Pat. No. 6,893,460 on May 17, 2005, Ser. No. 10/270,252, issued as U.S. Pat. No. 6,730,118 on May 4, 2004, and Ser. No. 10/637,882, which published as US2004-0039436 on Feb. 26, 2004, the entire contents of which are incorporated herein by reference, disclose and implantable prosthetic valve that comprises a support sent to be initially crimped in a narrow configuration suitable for catherization through the body duct to a target location.


Key features of any valve where sutures to hold the replacement valve into position are to be eliminated or reduced are: durability, low-pressure gradient across the valve, sufficient seal around the valve to prevent perivalvular leak, and prevent migration. Therefore, it would be desirable to provide an implantable valve that with features that aim to increase durability, reduce pressure gradient across the valve, and provide an adequate seal around the valve and prevent migration.


SUMMARY OF THE INVENTION

The present invention provides a valve prosthesis that in one embodiment comprises a support stent, comprised of a deployable construction adapted to be initially crimped in a narrow configuration suitable for catherization through the body ducts to a target location and adapted to be deployed by exerting substantially radial forces from within by means of a deployment device to a deployed state in the target location, the support stent provided with a plurality of longitudinally rigid support beams of fixed length; and a valve assembly comprising a flexible conduit having an inlet end and an outlet, made of pliant material attached to the support beams providing collapsible slack portions of the conduit at the outlet, whereby when flow is allowed to pass through the valve prosthesis device from the inlet to the outlet the valve assembly is kept in an open position whereas a reverse flow is prevented as the collapsible slack portions of the valve assembly collapse inwardly providing blockage to the reverse flow.


In another embodiment of the present invention, the support stent comprises an annular frame.


In yet another embodiment of the present invention, the support stent is made out of stainless steel.


In yet another embodiment of the present invention, said valve assembly has a tricuspid configuration.


In yet another embodiment of the present invention, said valve assembly is made from biocompatible material.


In yet another embodiment of the present invention, the valve assembly is made from pericardial tissue, or other biological tissue.


In yet another embodiment of the present invention, said valve assembly is made from biocompatible polymers.


In yet another embodiment of the present invention, the valve assembly is made from materials selected from the group consisting of polyurethane and polyethylene terphthalane.


In yet another embodiment of the present invention, the valve assembly comprises a main body made from polyethylene terphthalane and leaflets made from polyurethane.


In yet another embodiment of the present invention, said support stent is made from nickel titanium alloys.


In yet another embodiment of the present invention, the support beams are substantially equidistant and substantially parallel so as to provide anchorage for the valve assembly.


In yet another embodiment of the present invention, the support beams are provided with bores so as to allow stitching or tying of the valve assembly to the beams.


In yet another embodiment of the present invention, the support beams are not provided with bores so as to allow extra rigidity to the valve support structures.


In yet another embodiment of the present invention, the support beams are chemically adhered to the support stent.


In yet another embodiment of the present invention, said valve assembly is riveted to the support beams.


In yet another embodiment of the present invention, said beams are manufactured by injection using a mold, or by machining.


In yet another embodiment of the present invention, said valve assembly is rolled over the support stent at the inlet.


In yet another embodiment of the present invention, said valve device is manufactured using forging or dipping techniques.


In yet another embodiment of the present invention, said valve assembly leaflets are longer than needed to exactly close the outlet, thus when they are in the collapsed state substantial portions of the leaflets fall on each other creating better sealing.


In yet another embodiment of the present invention, said valve assembly is made from coils of a polymer, coated by a coating layer of same polymer.


In yet another embodiment of the present invention, said polymer is polyurethane.


In yet another embodiment of the present invention, the support stent is provided with heavy metal markers so as to enable tracking and determining the valve device position and orientation.


In yet another embodiment of the present invention, the heavy metal markers are selected from gold, platinum, iridium, tantalum, cobalt, chrome, and titanium alloys.


In yet another embodiment of the present invention, the valve assembly leaflets are provided with radio-opaque materials at the outlet so as to help tracking the valve device operation in vivo.


In yet another embodiment of the present invention, said radio-opaque material comprises gold thread.


In yet another embodiment of the present invention, the diameter of said support stent when fully deployed is in the range of from about 15 to about 33 mm.


In yet another embodiment of the present invention, the diameter of said support stent may be expanded from about 4 to about 25 mm.


In yet another embodiment of the present invention, the diameter of said support stent may be expanded from about 10 mm to about 25 mm.


In yet another embodiment of the present invention, the support beams are provided with bores and wherein the valve assembly is attached to the support beams by means of U-shaped rigid members that are fastened to the valve assembly and that are provided with extruding portions that fit into matching bores on the support beams.


In yet another embodiment of the present invention, the support beams comprise rigid support beams in the form of frame construction, and the valve assembly pliant material is inserted through a gap in the frame and a fastening rod is inserted through a pocket formed between the pliant material and the frame and holds the valve in position.


In yet another embodiment of the present invention, the main body of the valve assembly is made from coiled wire coated with coating material.


In yet another embodiment of the present invention, the coiled wire and the coating material is made from polyurethane.


In yet another embodiment of the present invention, a strengthening wire is interlaced in the valve assembly at the outlet of the conduit so as to define a fault line about which the collapsible slack portion of the valve assembly may flap.


In yet another embodiment of the present invention, the strengthening wire is made from nickel titanium alloy.


In yet another embodiment of the present invention, there is provided a valve prosthesis device suitable for implantation in body ducts, the device comprising a main conduit body having an inlet and an outlet and pliant leaflets attached at the outlet so that when a flow passes through the conduit from the inlet to the outlet the leaflets are in an open position allowing the flow to exit the outlet, and when the flow is reversed the leaflets collapse so as to block the outlet, wherein the main body is made from polyethylene terphtalate and collapsible leaflets are made from polyurethane.


In yet another embodiment of the present invention, support beams made from polyurethane are provided on the main body and wherein the leaflets are attached to the main body at the support beams.


In yet another embodiment of the present invention, said support beams are chemically adhered to the main body.


In yet another embodiment of the present invention, there is provided a valve prosthesis device suitable for implantation in body ducts, the device comprising:


A support stent, comprised of a deployable construction adapted to be initially crimped in a narrow configuration suitable for catherization through the body duct to a target location and adapted to be deployed by exerting substantially radial force from within by means of a deployment device to a deployed state in the target location, the support stent provided with a plurality of longitudinally rigid support beams of fixed length; a valve assembly comprising a flexible conduit having an inlet and an outlet, made of pliant material attached to the support beams providing collapsible slack portions of the conduit at the outlet; and substantially equidistant rigid support beams interlaced or attached to the slack portion of the valve assembly material, arranged longitudinally


In yet another embodiment of the present invention, the multiple plates are adapted to move simultaneously by means of a lever and transmission.


In yet another embodiment of the present invention, there is provided a method for deploying an implantable prosthesis valve device at the natural aortic valve position at the entrance to the left ventricle of a myocardium of a patient, the method comprising the steps of: (a) providing a balloon catheter having a proximal end and a distal end, having a first and second independently inflatable portions, the first inflatable portion located at the distal end of the catheter and the second inflatable portion adjacently behind the first inflatable portion; (b) providing a guiding tool for guiding the balloon catheter in the vasculature of the patient; (c) providing a deployable implantable valve prosthesis device adapted to be mounted on the second inflatable portion of the balloon catheter; (d) guiding the balloon catheter through the patient's aorta using the guiding tool, the valve device mounted over the second inflatable portion of the balloon catheter until the first inflatable portion of the balloon catheter is inserted into the left ventricle, whereas the second inflatable portion of the balloon catheter is positioned at the natural aortic valve position; (e) inflating the first inflatable portion of the balloon catheter so as to substantially block blood flow through the natural aortic valve and anchor the distal end of the balloon catheter in position; (f) inflating the second inflatable portion of the balloon catheter so as to deploy the implantable prosthesis valve device in position at the natural aortic valve positions; (g) deflating the first and second inflatable portions of the balloon catheter; and (h) retracting the balloon catheter and removing it from the patient's body.


In yet another embodiment of the present invention, the guiding tool compromises a guide wire.


In some further embodiments, the present invention provides a method for deploying an implantable prosthesis valve device at the natural aortic valve position at the entrance to the left ventricle of the myocardium of a patient, the method comprising the steps of: (a) providing a balloon catheter having a proximal end a distal end, having a first and second independently inflatable portions, the first inflatable portion located at the distal end of the catheter and the second inflatable portion adjacently behind the first inflatable portion; (b) providing a guiding tool for guiding the balloon catheter in the vasculature of the patient; providing a deployable implantable valve prosthesis device adapted to be mounted on the first inflatable portion of the balloon catheter, and a deployable annular stent device adapted to be mounted over the second inflatable portion of the balloon catheter, the deployable implantable valve prosthesis device and the deployable annular stent kept at a predetermined distance apart; (d) guiding the balloon catheter through the patient's aorta using the guiding tool, the valve device mounted over the first inflatable portion of the balloon catheter and the deployable annular stent mounted over the second inflatable portion of the balloon catheter, until the first inflatable portion of the balloon catheter is positioned at the natural aortic valve position; (e) inflating the second inflatable portion of the balloon catheter so that the deployable stent device is deployed within the aorta thus anchoring the deployable annular stent and the coupled valve device in position; (f) inflating the first inflatable portion of the balloon catheter so as to deploy the implantable prosthesis valve device in position at the natural aortic valve position; (g) deflating the first and second inflatable portions of the balloon catheter; and (h) retracting the balloon catheter and removing it from the patient's body.


It is one object of the valve device described in the present invention to presents a novel means of attaching a tissue valve to a support structure. The means of attaching the valve to the support structure may increase the durability of the valve, reduce the pressure gradient across the valve, provide a seal around the valve to prevent perivalvular leak, and prevent migration. The valves of the present invention may comprise a plurality of joined leaflets with a corresponding number of commissural tabs. Generally, however, the desired valve will contain two to four leaflets and commissural tabs.


In an embodiment of the present invention, the valves are similar to the valves disclosed in U.S. patent application Ser. Nos. 09/772,526, 09/853,463, 09/924,970, 10/121,208, 10/122,035, 10/153,286, 10/153,290, the disclosures of all of which are incorporated by reference in their entirety herein. The diameter of the valves described in these applications may be equal or less than the orifice diameter of the support structure of the valve.


In yet another embodiment of the present invention, the valves described in U.S. patent application Ser. Nos. 09/772,526, 09/853,463, 09/924,970, 10/121,208, 10/122,035, 10/153,286, 10/153,290, the valves are sized such that the effective valve diameter is 1-5 mm less than the diameter of the orifice of the support structures of the valve. This size will help prevent the valve leaflets from hitting the support structure.


In yet another embodiment of the present invention, the valves are made of equine pericardium.


In yet another embodiment of the present invention, a cuff (e.g. cloth) portion of the valve assembly is wrapped around the support stent at the inlet. This may enhance stability of the stent, but further, the cuff portion described in the current invention may be used for attaching sutures. Most importantly, the cuff portion of the present invention is intended to reduce perivalvular leak around the valve. Using such a cuff to create a seal between the valve structure and the aorta prevents perivalvular leak and is especially important in patients whose annulus (or landing zone for the valve) is calcified or irregular. The cuff may also prevent migration of the valve as the friction between the valve device and the surrounding is increased. Utilizing a cloth cuff may also induce tissue ingrowth. The cloth may initially clot when it is exposed to blood. The cloth may further induce endothelial and fibroblast, and hence tissue ingrowth into the cloth cuff.


In yet another embodiment of the present invention the cloth cuff creates a step between a thin cloth covering around the inlet portion of the valve assembly that moves up to a much thicker cloth cuff slightly further downstream in the assembly. Such a “lip” or “step” may help position and secure the valve prosthesis at the correct position.


In yet other embodiments of the present invention, the scalloped inflow edge described in U.S. application Ser. Nos. 09/772,526, 09/853,463, 09/924,970, 10/121,208, 10/122,035, 10/153,286, 10/153,290, is sutured onto the cuff portion of the valve assembly described above. Another use of the cuff is thus to allow a valve with a scalloped inflow edge to be attached to a non-scalloped stent.


In yet other embodiments of the present invention, the support beams of the stent are extended at the inflow portion to accommodate the length of longer valves such as the ones described in U.S. application Ser. Nos. 09/772,526, 09/853,463, 09/924,970, 10/121,208, 10/122,035, 10/153,286, 10/153,290.


In yet another embodiment of the present invention, the support beams form eyelets at the outflow edge that the tabs of the valves described in U.S. application Ser. Nos. 09/772,526, 09/853,463, 09/924,970, 10/121,208, 10/122,035, 10/153,286, 10/153,290 may be attached to. The valve tabs may be sutured to the eyelets around the perimeter of the eyelet. Such a configuration helps distribute the stress around the tabs and reduce the wear and tear on the commissural posts of the valve.


In yet another embodiment of the present invention, the support beam eyelets described above are covered with cloth. Covering the eyelets and tabs with cloth may help induce tissue ingrowth.


In yet another embodiment of the present invention, the valve device is made such that it cannot be crimped down beyond the diameter of a typical femoral artery or a femoral vein (where the catheter can typically be no more than 8 mm). In other words, the valve device is made such that it cannot be implanted through the femoral artery or femoral vein.


In yet another embodiment of the present invention, the valve device is crimped just after it has been manufactured, and shipped from the manufacturer in the crimped state to the hospital or where it is to be implanted.


In yet another embodiment of the present invention, the stent is made out of a memory shaped metal or a memory shaped polymer.


In yet another embodiment of the present invention, the stent of the valve device is made to be balloon expandable.


In yet another embodiment of the present invention, the stent of the valve device is made to be self-expandable.


The present invention provides systems and devices for the replacement of physiological valves. In one embodiment of the present invention, the replacement valve assemblies are adapted to fit substantially within the valve sinuses. Because the devices and procedures provided by the present invention eliminate or reduce the need for suturing, time spent in surgery is significantly decreased, and the risks associated with surgery are minimized. Further, the devices of the present invention are suitable for delivery by cannula or catheter.


In yet another embodiment of the present invention, the stent of the valve device is made such as to expand into the sinus regions during balloon expansion.


In yet another embodiment of the present invention, the stent of the valve devices is made such as to expand into the sinus region during self-expansion.


In one embodiment of the present invention a valve anchoring structure is provided that is dimensioned to be placed substantially within the valve sinus. In this embodiment, the valve anchoring structure extends substantially across the length of the valve sinus region.


In another embodiment of the present invention a valve assembly is provided, comprising a valve and anchoring structure, in which the valve comprises a body having a proximal end and a distal end, an inlet at the proximal end, and an outlet at the distal end. The inlet comprises an inflow annulus, with either a scalloped or straight edge. The outlet comprises a plurality of tabs that are supported by the anchoring means at the distal end. In an embodiment of the invention, the plurality of tabs is spaced evenly around the circumference of the valve.


In yet another embodiment of the present invention, a valve assembly is provided in which there is minimal or no contact between the valve and anchoring structure.


In still another embodiment of the present invention, a valve assembly is provided in which the valve is capable of achieving full opening and full closure without contacting the anchoring structure.


In yet another embodiment of the present invention, a valve assembly is provided in which the vertical components of the anchoring structure are limited to the commissural posts between sinus cavities, thereby minimizing contact between mechanical components and fluid, as well as providing flow to vessels located in the valve sinus.


In still another embodiment of the present invention, a valve is provided that firmly attaches to the valve sinus, obviating the need for suturing to secure the valve placement.


In a further embodiment of the present invention, a valve assembly is provided in which the anchoring structure may be collapsed to at least fifty percent of its maximum diameter.


In still a further embodiment of the present invention, an expansion and contraction device is provided to facilitate implantation of the valve and anchoring structure.


In another embodiment, the present invention provides adhesive means for securing the valve assembly in a valve sinus.


In yet another embodiment of the present invention, a valve sizing apparatus is provided for the noninvasive determination of native valve size.





DESCRIPTION OF DRAWINGS

To better understand the present invention and appreciate its practical applications, the following Figures are provided and referenced hereafter. It should be noted that the Figures are given as examples only and in no way limit the scope of the invention.



FIG. 1 shows the valve structure, stent, or frame seen from the side.



FIG. 2 shows the valve structure, stent, or frame seen from the side.



FIG. 3 shows the valve structure, stent, or frame seen from an isometric view.



FIG. 4 shows the valve structure, stent, or frame seen from the top (i.e. at the outflow side).



FIG. 5 shows the frame with a cloth cover around the inflow edge.



FIG. 6 shows the frame with a cloth cover around the inflow edge.



FIG. 7 shows the frame with cloth cover around the inflow edge.



FIG. 8 shows the frame with cloth cover around the inflow edge.



FIG. 9 shows the frame with cloth cover around the inflow edge. The valve is also attached in this figure. The tabs of the valve are aligned with the eyelets of the frame.



FIG. 10 shows the frame with cloth cover around the inflow edge. The valve is also attached in this figure. The tabs of the valve are aligned with the eyelets of the frame.



FIG. 11 shows the frame with cloth cover around the inflow edge. The valve is also attached in this figure. The tabs of the valve are aligned with the eyelets of the frame.



FIG. 12 shows the frame with cloth cover around the inflow edge. The valve is also attached in this figure. The tabs of the valve are aligned with the eyelets of the frame.



FIG. 13 shows the frame with cloth cover around the inflow edge. The valve is also attached in this figure. The tabs of the valve are aligned with the eyelets of the frame. Cloth has been added and keeps the valve tabs attached to the frame eyelets.



FIG. 14 shows the frame with cloth cover around the inflow edge. The valve is also attached in this figure. The tabs of the valve are aligned with the eyelets of the frame. Cloth has been added and keeps the valve tabs attached to the frame eyelets.



FIG. 15 shows the frame with cloth cover around the inflow edge. The valve is also attached in this figure. The tabs of the valve are aligned with the eyelets of the frame. Cloth has been added and keeps the valve tabs attached to the frame eyelets.



FIG. 16 shows the frame with cloth cover around the inflow edge. The valve is also attached in this figure. The tabs of the valve are aligned with the eyelets of the frame. Cloth has been added and keeps the valve tabs attached to the frame eyelets.



FIG. 17 shows one of the leaflets described in U.S. application Ser. Nos. 09/772,526, 09/853,463, 09/924,970, 10/121,208, 10/122,035, 10/153,286, 10/153,290 and shows how this is aligned with the frame and frame eyelets. The cloth cuff around the inflow edge has been removed for clarity.



FIG. 18 shows the outflow side of a prototype valve prosthesis.



FIG. 19 shows the inflow side of a prototype valve prosthesis.



FIG. 20 shows a side view of a prototype valve prosthesis.



FIG. 21 shows the stent of the valve assembly crimped down to 7.5 mm



FIG. 22 shows the assembly of the valve tab to frame eyelet



FIG. 23 shows final cloth covering of tab/eyelet assembly.





DETAILED DESCRIPTION

A main aspect of the present invention is the introduction of several novel designs for an implantable prosthesis valve. Another aspect of the present invention is the disclosure of several manufacture methods for the manufacturing of implantable prosthesis valves in accordance with the present invention. A further aspect of the present invention is the provision of novel deployment and positioning techniques suitable for the valve of the present invention.


Basically the implantable prosthetic valve of the present invention comprises a leafed-valve assembly, preferably tricuspid but not limited to tricuspid valves only, consisting of a conduit having an inlet end and an outlet, made of pliant material arranged so as to present collapsible walls at the outlet. The valve assembly is mounted on a support structure such as a stent adapted to be positioned at a target location within the body duct and deploy the valve assembly by the use of deploying means, such as a balloon catheter or similar devices. In embodiments suitable for safe and convenient percutaneous positioning and deployment the annular frame is able to be posed in two positions, a crimped position where the conduit passage cross-section presented is small so as to permit advancing the device towards its target location, and a deployed position where the frame is radial extended by forces exerted from within (by deploying means) so as to provide support against the body duct wall, secure the valve in position and open itself so as to allow flow through the conduit.


The valve assembly can be made from biological matter, such as a natural tissue, pericardial tissue or other biological tissue. Alternatively, the valve assembly may be made form biocompatible polymers or similar materials. Homograph biological valves need occasional replacement (usually within 5 to 14 years) and this is a consideration the surgeon must take into account, when selecting the proper valve implant according to the patient type. Metal mechanical valves, which have better durability qualities, carry the associated risk of long-term anticoagulation treatment.


The frame can be made from shape memory alloys such as nickel titanium (nickel titanium shape memory alloys, or NiTi, as marketed, for example, under the brand name Nitinol), or other biocompatible metals. The percutaneously implantable embodiment of the implantable valve of the present invention has to be suitable for crimping into a narrow configuration for positioning and expandable to a wider, deployed configuration so as to anchor in position in the desired target location.


The support stent is preferably annular, but may be provided in other shapes too, depending on the cross-section shape of the desired target location passage.


Manufacturing of the implantable prosthetic valve of the present invention can be done in various methods, for example, by dipping, injection, electrospinning, rotation, ironing, or pressing.


The attachment of the valve assembly to the support stent can be accomplished in several ways, such as by sewing it to several anchoring points on the support stent, or riveting it, pinning it, or adhering it, to provide a valve assembly that is cast or molded over the support stent, or use any other suitable way of attachment.


To prevent leakage from the inlet it is optionally possible to roll up some slack wall of the inlet over the edge of the frame so as to present rolled-up sleeve-like portion at the inlet.


Furthermore, floating supports may be added to enhance the stability of the device and prevent it from turning inside out.


An important aspect of certain embodiments of the present invention is the provision of rigid support beams incorporated with the support stent that retains its longitudinal dimension while the entire support stent may be longitudinally or laterally extended.


The aforementioned embodiments as well as other embodiments, manufacturing methods, different designs and different types of devices are discussed and explained below with reference to the accompanying drawings. Note that the drawings are only given for the purpose of understanding the present invention and presenting some preferred embodiments of the present invention, but this does in no way limit the scope of the present invention as defined in the appended claims.


Reference is now made to FIG. 1, which illustrates a valve support structure or frame shown in a deployed position. The frame has an inlet 9 and an outlet side 10. The frame is arranged in a net-like frame designed to be crimped evenly so as to present a narrow configuration and be radially deployable so as to extend to occupy the passage at the target location for implantation in a body duct. Support beams 3 are provided on annular support stent 2 to provide rigidity and anchorage to the valve. Support beams 3 may be provided with bores to provide attachment for a valve. In the current Figure, the support beams are solid as to provide extra rigidity to the stent. The support beams 3 transition into oval eyelets 1 at the outflow edge.



FIGS. 2-4 show the same frame seen in FIG. 1 from different perspectives.


Note that the entire valve structure is adapted to be radially crimped and radially expanded, and this lends to provide ease of navigation through narrow passages in the vasculature during positioning of the device and adequate deployment on the final location. This is made possible by the provision of a collapsible support stent structure. However, the support beams always maintain the same length. Because the support beams maintain the same length, the distance between the inflow edge and the tab attachments of the valve are maintained during crimping and expansion. This allows the valve to function properly. In prior art implantable valve devices the entire support structure changes its dimensions from its initial first crimped position and final deployed position, and this means that in the attachment of the valve assembly to the support structure one must take into consideration these dimension changes and leave slack material so that upon deployment of the device the valve assembly does not tear or deform. In the valve device of the present invention there is no relative movement between the valve assembly and the support beams (along the longitudinal central axis of the device). As a result, the valve device of the present invention acquires greater durability and is capable of withstanding the harsh conditions prevailing within the heart. The novel design of the valve device of the present invention leads to longitudinal strength and rigidity whereas its collapsible support structure results in radial flexibility.



FIG. 5 shows the cloth cuff (4 and 5) at the inflow edge of the stent. The cloth cuff has a circular inlet end and a circular outlet end. The cloth cuff may consist of a thin cloth cuff 5 and a thicker cloth cuff 4 and thus create a lip 11 at the intersection between these two cuffs. This “lip” or “step” may help position and secure the valve prosthesis at the correct position. It may, for example, help hold the valve prosthesis at the inflow annulus when placed in the aortic position.



FIGS. 6-8 show the same frame and tissue cuffs seen in FIG. 5 from different perspectives.



FIG. 9 shows one of the valves 6 disclosed in U.S. patent application Ser. Nos. 09/772,526, 09/853,463, 09/924,970, 10/121,208, 10/122,035, 10/153,286, 10/153,290. The tabs 7 of the valve are aligned with the eyelets 1 of the support beams. The overall size of the eyelets 1 match the size of the tabs 7. The valve 6 is attached at the inflow side of the frame 9 and is sutured to the cloth cuff 5 and 4.



FIGS. 10-12 show the same valve assembly seen in FIG. 9 from different perspectives.



FIG. 13 shows the complete valve assembly. In this Figure, the tabs 7 and the eyelets 1 have been covered with cloth 8. Covering the tabs 7 with a cloth cuff may induce tissue ingrowth. The cloth may initially clot when it is exposed to blood. The cloth may further induce endothelial and fibroblast, and hence tissue ingrowth. Inducing tissue ingrowth will reduce the loads imposed on the stent. Covering the tabs 7 and the eyelets 1 with cloth 8 in this manner will also help distribute the load seen by the commissural posts across the entire tab, hence reducing wear and tear on the commissural posts of the valve.



FIGS. 14-16 show the same valve assembly seen in FIG. 13 from different perspectives.



FIG. 17 shows one of the leaflets 12 described in U.S. application Ser. Nos. 09/772,526, 09/853,463, 09/924,970, 10/121,208, 10/122,035, 10/153,286, 10/153,290 and shows how this is aligned with the frame 15 and frame eyelets 13. The cloth cuff around the inflow edge has been removed for clarity. Another embodiment that is evident in FIG. 17 is how the scalloped edge of the leaflet 14 is positioned relative to the inlet of the stent 15.



FIGS. 18-20 show pictures of a prototype valve that has been assembled.



FIG. 21 shows a picture of a stent crimped to 7.5 mm.



FIG. 22 shows the assembly of the valve tab to frame eyelet.



FIG. 23 shows the final cloth covering of tab/eyelet assembly.


A typical size of an aortic prosthesis valve is from about 19 to about 31 mm in diameter. A maximal size of a catheter inserted into the femoral artery should be no more than 8 mm in diameter. The present invention introduces a device, which has the ability to change its diameter from about 4 mm to about 33 mm. Artificial valves are not new; however, artificial valves in accordance with the present invention posses the ability to change shape and size for the purpose of delivery and as such are novel. These newly designed valves require new manufacturing methods and technical inventions and improvements, some of which were described herein.


As described before, one embodiment of the present invention is to make it impossible for the stent to be crimped down below the size of the femoral artery or vein. In other words, one may create mechanical stops or add tissue or cloth in a manner as to prevent the stent from being capable of being crimped further down than beyond the size of the femoral artery or vein. In this manner, the stent is made such that it intentionally cannot be used through a femoral vein or femoral artery access. Creating such size constraints on the valve assembly may make it possible to create a sturdier device for prolonging the longevity of the valve assembly. Such a device could be implanted through the apex of the heart, as described in details in a U.S. patent application no. 10/831,770 submitted Apr. 23, 2004 entitled “Method and System for Cardiac Valve Delivery”. An early version of this document is submitted at the same time as the current provisional. No application number exists at this point. The application is appended to this provisional patent application, and is hereby included in this application in its entirety.


As mentioned earlier, the material of which the valve is made from can be either biological or artificial. In any case new technologies are needed to create such a valve.


To attach the valve to the body, the blood vessels determine the size during delivery, and the requirements for it to work efficiently, there is a need to mount it on a collapsible construction which can be crimped to a small size, be expanded to a larger size, and be strong enough to act as a support for the valve function. This construction, which is in somewhat similar to a large “stent”, can be made of different materials such as Nitinol, biocompatible stainless steel, polymeric material or a combination of all. Special requirement for the stent are a subject of some of the embodiments discussed herein.


The mounting of the valve onto a collapsible stent is a new field of problems. New solutions to this problem are described herein.


Another major aspect of the design of the valve of the present invention is the attachment to the body.


Yet another major aspect of the valve apparatus is the attachment of the valve to the frame.


In the traditional procedure the valve is sutured in place by a complicated suturing procedure. In the case of the percutaneous procedure there is no direct access to the implantation site therefore different attachment techniques are needed.


Another new problem that is dealt herein is the delivery procedure, which is new and unique. Positioning of the device in the body in an accurate location and orientation requires special marking and measuring methods of the device and surgical site as was disclosed herein.


Artificial polymer valves require special treatment and special conditions when kept on a shelf, as well as a special sterilization procedure. One of the consequences of the shelf treatment is the need to crimp the valve during the implantation procedure. A series of devices and inventions to allow the crimping procedure are disclosed herein.


It should be clear that the description of the embodiments and attached Figures set forth in this specification serves only for a better understanding of the invention, without limiting its scope as covered by the following claims.


While the invention has been described with reference to the specific embodiments thereof, those skilled in the art will be able to make various modifications to the described embodiments of the invention without departing from the true spirit and scope of the invention. The terms and descriptions used herein are set forth by way of illustration only and are not meant as limitations. Those skilled in the art will recognize that these and other variations are possible within the spirit and scope of the invention as defined in the following claims and their equivalents.

Claims
  • 1. A prosthetic valve assembly comprising: a support structure having an inlet end and an outlet end, wherein the support structure includes a plurality of longitudinally rigid support beams, said support structure configured to be radially collapsible and expandable;a valve comprising a pliant material having an inlet and an outlet, wherein said pliant material has a plurality of tabs at said outlet, and wherein said plurality of tabs are attached to said support beams at said outlet end of said support structure; anda cuff operably attached to an outer surface of said support structure at said inlet of said support structure, wherein said cuff is disposed radially outside of said support beams, wherein said cuff has a radial lip configured to facilitate positioning and securing said valve assembly in a body lumen, wherein said cuff comprises a first cylindrical portion and a second cylindrical portion, said first cylindrical portion having greater thickness than said second cylindrical portion, wherein the first cylindrical portion is disposed downstream of the second cylindrical portion, and wherein said radial lip is defined by an interface of said first cylindrical portion and said second cylindrical portion.
  • 2. The prosthetic valve assembly of claim 1 wherein said cuff comprises a material configured to facilitate tissue ingrowth.
  • 3. The prosthetic valve assembly of claim 1 wherein said cuff comprises a cloth material.
  • 4. The prosthetic valve assembly of claim 1 wherein said plurality of tabs are commissural tabs that are operably attached to eyelets on said outlet end of at least two of said plurality of longitudinally rigid support beams.
  • 5. The prosthetic valve assembly of claim 4 wherein said plurality of tabs are sutured to said eyelets around a perimeter of each of said eyelets.
  • 6. The prosthetic valve assembly of claim 1 further comprising cloth portions covering said plurality of tabs and said outlet end of said support structure.
  • 7. The prosthetic valve assembly of claim 1 wherein said support structure comprises a material selected from the group consisting of memory shaped metals, memory shaped polymers, biocompatible stainless steel and polymeric material.
  • 8. The prosthetic valve assembly of claim 7 wherein said support structure comprises polyethylene terphthalene.
  • 9. The prosthetic valve assembly of claim 1 wherein said valve comprises at least two leaflets having tabs integrally formed thereon.
  • 10. The prosthetic valve assembly of claim 9 wherein said leaflets comprise a material selected from the group consisting of natural tissue and biocompatible materials.
  • 11. The prosthetic valve assembly of claim 10 wherein said natural tissue is pericardial tissue.
  • 12. The prosthetic valve assembly of claim 10 wherein said biocompatible material is polyurethane.
  • 13. The prosthetic valve assembly of claim 1 wherein said support structure is configured to be radially collapsible to a diameter of 4-25 mm while retaining a fixed longitudinal length.
  • 14. The prosthetic valve assembly of claim 1 wherein said support structure is configured to be radially expandable to a diameter of 10-33 mm while retaining a fixed longitudinal length.
  • 15. The prosthetic valve assembly of claim 1 wherein said support structure comprises an annular frame and said valve has a generally tubular shape, said valve having an outer diameter that is 1-5 mm smaller than an inner diameter of said support structure.
  • 16. The prosthetic valve assembly of claim 1 wherein said valve comprises a tricuspid configuration.
  • 17. The prosthetic valve assembly of claim 1 wherein said plurality of longitudinally rigid support beams are spaced equidistantly around said support structure.
  • 18. The prosthetic valve assembly of claim 17 wherein said plurality of longitudinally rigid support beams are positioned parallel to one another.
  • 19. The prosthetic valve assembly of claim 1 wherein said valve is attached to said cuff.
  • 20. The prosthetic valve assembly of claim 1 wherein said plurality of longitudinally rigid support beams are attached to said support structure with rivets or an adhesive.
  • 21. The prosthetic valve assembly of claim 1 wherein said plurality of longitudinally rigid support beams are integrally formed with said support structure.
  • 22. The prosthetic valve assembly of claim 1 wherein said support structure has at least one marker configured to track and determine position and orientation of said prosthetic valve assembly.
  • 23. The prosthetic valve assembly of claim 22 wherein said at least one marker comprises a metal selected from the group consisting of gold, platinum, iridium, tantalum, cobalt, chrome and titanium alloys.
  • 24. The prosthetic valve assembly of claim 1 wherein said valve has a radio-opaque material at said outlet, said radio-opaque material configured to facilitate in vivo tracking of said valve assembly.
  • 25. The prosthetic valve assembly of claim 24 wherein said radio-opaque material comprises gold thread.
  • 26. The prosthetic valve assembly of claim 1 wherein said valve has collapsible slack portions at said outlet, said collapsible slack portions configured to allow blood to pass through said prosthetic valve assembly when flowing from said inlet end to said outlet thereby holding said collapsible slack portions in an open position, said collapsible slack portions further configured to prevent reverse blood flow by collapsing inwardly and maintaining said collapsible slack portions in a closed position.
  • 27. The prosthetic valve assembly of claim 26 further comprising a strengthening wire disposed along said outlet of said valve and configured to support said collapsible slack portions.
  • 28. The prosthetic valve assembly of claim 27 wherein said strengthening wire comprises nickel titanium.
  • 29. A method for implanting a prosthetic valve assembly comprising: (a) providing a catheter having a proximal end and a distal end;(b) mounting said prosthetic valve assembly on said distal end, said prosthetic valve assembly comprising (i) a support structure having an inlet end, an outlet end and a plurality of longitudinally rigid support beams disposed thereon, said support structure configured to be radially collapsible and expandable while retaining a fixed longitudinal length;(ii) a valve comprised of a pliant material having an inlet end and an outlet, said pliant material having a plurality of tabs at said outlet configured to be operably attached to said support beams at said outlet end of said support structure; and(iii) a cuff operably attached to an outer surface of said support structure at said inlet of said support structure, wherein said cuff is disposed radially outside of said support beams, wherein said cuff has a radial lip configured to facilitate positioning and securing said valve assembly in a body lumen, wherein said cuff comprises a first cylindrical portion and a second cylindrical portion, said first cylindrical portion having greater thickness than said second cylindrical portion, wherein the first cylindrical portion is disposed downstream of the second cylindrical portion, and wherein said radial lip is defined by an interface of said first cylindrical portion and said second cylindrical portion;(c) guiding said catheter through said body lumen to a target site with a guiding tool;(d) deploying said prosthetic valve assembly at said target location; and(e) retracting said catheter.
  • 30. The method of claim 29 wherein said guiding tool comprises a guidewire.
  • 31. The method of claim 29 wherein said cuff is comprised of a material configured to facilitate tissue ingrowth.
  • 32. The method of claim 29 wherein said cuff comprises a cloth material.
  • 33. The method of claim 29 wherein said plurality of tabs are commissural tabs that are operably attached to eyelets on said outlet end of at least two of said plurality of longitudinally rigid support beams.
  • 34. The method of claim 33 further comprising suturing said plurality of tabs to said eyelets around a perimeter of each of said eyelets.
  • 35. The method of claim 29 further comprising covering said plurality of tabs and said outlet end of said support structure with cloth portions for promoting tissue ingrowth.
  • 36. The method of claim 29 wherein said support structure comprises a material selected from the group consisting of memory shaped metals, memory shaped polymers, biocompatible stainless steel and polymeric material.
  • 37. The method of claim 36 wherein said support structure comprises polyethylene terphthalene.
  • 38. The method of claim 29 wherein said valve comprises at least two leaflets having tabs integrally formed thereon.
  • 39. The method of claim 38 wherein said leaflets comprise a material selected from the group consisting of natural tissue and biocompatible materials.
  • 40. The method of claim 39 wherein said natural tissue is pericardial tissue.
  • 41. The method of claim 39 wherein said biocompatible material is polyurethane.
  • 42. The method of claim 29 wherein the step for guiding said catheter through said body lumen to a target site with said guiding tool further comprises radially collapsing said prosthetic valve assembly to a diameter of 4-25 mm while maintaining a fixed longitudinal length of said prosthetic valve assembly.
  • 43. The method of claim 29 wherein the step for deploying said prosthetic valve assembly at said target location further comprises radially expanding said prosthetic valve assembly to a diameter of 10-33 mm while retaining a fixed longitudinal length of said prosthetic valve assembly.
  • 44. The method of claim 29 further comprising sizing said valve and said support structure to allow said valve to fully open and close without contacting said support structure.
  • 45. The method of claim 29 wherein said valve comprises a tricuspid configuration.
  • 46. The method of claim 29 wherein said plurality of longitudinally rigid support beams are spaced equidistantly around said support structure.
  • 47. The method of claim 46 wherein said plurality of longitudinally rigid support beams are positioned parallel to one another.
  • 48. The method of claim 29 further comprising adhering said plurality of longitudinally rigid support beams to said support structure with an adhesive.
  • 49. The method of claim 29 further comprising attaching said plurality of longitudinally rigid support beams to said support structure with rivets.
  • 50. The method of claim 29 further comprising integrally forming said plurality of longitudinally rigid support beams with said support structure.
  • 51. The method of claim 29 further comprising providing at least one marker configured to track and determine position and orientation of said prosthetic valve assembly.
  • 52. The method of claim 51 wherein said at least one marker comprises a metal selected from the group consisting of gold, platinum, iridium, tantalum, cobalt, chrome and titanium alloys.
  • 53. The method of claim 29 wherein said valve has a radio-opaque material at said outlet for facilitating in vivo tracking of said valve assembly.
  • 54. The method of claim 53 wherein said radio-opaque material comprises gold thread.
  • 55. The method of claim 29 further comprising attaching said valve to said support structure with at least one U-shaped rigid member wherein said plurality of longitudinally rigid support beams have bores configured to receive extruded portions of at least one U-shaped rigid member.
  • 56. The method of claim 29 wherein said plurality of longitudinally rigid support beams comprise a frame construction having a plurality of gaps therewithin, and further wherein said pliant material is inserted in at least one of said plurality of gaps.
  • 57. The method of claim 56 further comprising a fastening rod insertable through a pocket formed between said pliant material and said frame construction.
  • 58. The method of claim 29 wherein said support structure comprises a coiled wire coated with a coating material.
  • 59. The method of claim 58 wherein said coating material comprises polyurethane.
  • 60. The method of claim 29 wherein said valve has collapsible slack portions at said outlet, said collapsible portions configured to allow blood to pass through said prosthetic valve assembly when flowing from said inlet end to said outlet thereby holding said collapsible portions in an open position, said collapsible portions further configured to prevent reverse blood flow by collapsing inwardly and maintaining said collapsible portions in a closed position.
  • 61. The method of claim 60 further comprising a strengthening wire disposed along said outlet of said valve for supporting said collapsible portions.
  • 62. The method of claim 61 wherein said strengthening wire comprises nickel titanium.
  • 63. The method of claim 29 further comprising at least one inflatable portion on said distal end of said catheter, said inflatable portion configured to radially expand said prosthetic valve assembly for deploying said prosthetic valve assembly at said target location.
  • 64. The method of claim 29 wherein said support structure is radially self expanding for deploying said prosthetic valve assembly at said target location.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 11/112,757, filed Apr. 22, 2005, which claims the benefit of U.S. Provisional Application No. 60/565,118, filed Apr. 23, 2004, the entireties of which are hereby incorporated by reference

US Referenced Citations (587)
Number Name Date Kind
3657744 Ersek Apr 1972 A
3671979 Moulopoulos Jun 1972 A
3714671 Edwards et al. Feb 1973 A
3755823 Hancock Sep 1973 A
3795246 Sturgeon Mar 1974 A
3839741 Haller Oct 1974 A
3868956 Alfidi et al. Mar 1975 A
3874388 King et al. Apr 1975 A
4035849 Angell et al. Jul 1977 A
4056854 Boretos et al. Nov 1977 A
4222126 Boretos et al. Sep 1980 A
4233690 Akins Nov 1980 A
4265694 Boretos May 1981 A
4291420 Reul Sep 1981 A
4297749 Davis et al. Nov 1981 A
4339831 Johnson Jul 1982 A
4343048 Ross et al. Aug 1982 A
4345340 Rosen Aug 1982 A
4425908 Simon Jan 1984 A
4501030 Lane Feb 1985 A
4574803 Storz Mar 1986 A
4580568 Gianturco Apr 1986 A
4592340 Boyles Jun 1986 A
4610688 Silvestrini et al. Sep 1986 A
4612011 Kautzky Sep 1986 A
4662885 DiPisa, Jr. May 1987 A
4665906 Jervis May 1987 A
4681908 Broderick et al. Jul 1987 A
4710192 Liotta et al. Dec 1987 A
4787899 Lazarus Nov 1988 A
4787901 Baykut Nov 1988 A
4796629 Grayzel Jan 1989 A
4819751 Shimada et al. Apr 1989 A
4834755 Silvestrini et al. May 1989 A
4856516 Hillstead Aug 1989 A
4872874 Taheri Oct 1989 A
4878495 Grayzel Nov 1989 A
4878906 Lindemann et al. Nov 1989 A
4883458 Shiber Nov 1989 A
4909252 Goldberger Mar 1990 A
4917102 Miller et al. Apr 1990 A
4922905 Strecker May 1990 A
4966604 Reiss Oct 1990 A
4979939 Shiber Dec 1990 A
4986830 Owens et al. Jan 1991 A
4994077 Dobben Feb 1991 A
5007896 Shiber Apr 1991 A
5026366 Leckrone Jun 1991 A
5032128 Alonso Jul 1991 A
5047041 Samuels Sep 1991 A
5059177 Towne et al. Oct 1991 A
5085635 Cragg Feb 1992 A
5089015 Ross Feb 1992 A
5152771 Sabbaghian et al. Oct 1992 A
5163953 Vince Nov 1992 A
5167628 Boyles Dec 1992 A
5258023 Reger Nov 1993 A
5272909 Nguyen et al. Dec 1993 A
5295958 Shturman Mar 1994 A
5327774 Nguyen et al. Jul 1994 A
5332402 Teitelbaum et al. Jul 1994 A
5350398 Pavcnik et al. Sep 1994 A
5370685 Stevens Dec 1994 A
5397351 Pavcnik et al. Mar 1995 A
5411552 Andersen et al. May 1995 A
5415633 Lazarus et al. May 1995 A
5431676 Dubrul et al. Jul 1995 A
5443446 Shturman Aug 1995 A
5449384 Johnson Sep 1995 A
5480424 Cox Jan 1996 A
5489294 McVenes et al. Feb 1996 A
5489297 Duran Feb 1996 A
5496346 Horzewski et al. Mar 1996 A
5500014 Quijano et al. Mar 1996 A
5507767 Maeda et al. Apr 1996 A
5545209 Roberts et al. Aug 1996 A
5545211 An et al. Aug 1996 A
5545214 Stevens Aug 1996 A
5554185 Block et al. Sep 1996 A
5575818 Pinchuk Nov 1996 A
5580922 Park et al. Dec 1996 A
5591195 Taheri et al. Jan 1997 A
5609626 Quijano et al. Mar 1997 A
5645559 Hachtman et al. Jul 1997 A
5665115 Cragg Sep 1997 A
5667523 Bynon et al. Sep 1997 A
5674277 Freitag Oct 1997 A
5702368 Stevens et al. Dec 1997 A
5713953 Vallana et al. Feb 1998 A
5716417 Girard et al. Feb 1998 A
5746709 Rom et al. May 1998 A
5749890 Shaknovich May 1998 A
5766151 Valley et al. Jun 1998 A
5782809 Umeno et al. Jul 1998 A
5800456 Maeda et al. Sep 1998 A
5800508 Goicoechea et al. Sep 1998 A
5800527 Jansen et al. Sep 1998 A
5824041 Lenker Oct 1998 A
5824043 Cottone, Jr. Oct 1998 A
5824053 Khosravi et al. Oct 1998 A
5824056 Rosenberg Oct 1998 A
5824061 Quijano et al. Oct 1998 A
5824064 Taheri Oct 1998 A
5840081 Andersen et al. Nov 1998 A
5843158 Lenker et al. Dec 1998 A
5851232 Lois Dec 1998 A
5855597 Jayaraman Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5860966 Tower Jan 1999 A
5861028 Angell Jan 1999 A
5876448 Thompson et al. Mar 1999 A
5888201 Stinson et al. Mar 1999 A
5891191 Stinson Apr 1999 A
5906619 Olson et al. May 1999 A
5913842 Boyd et al. Jun 1999 A
5925063 Khosravi Jul 1999 A
5944738 Amplatz et al. Aug 1999 A
5957949 Leonhardt et al. Sep 1999 A
5968068 Dehdashtian et al. Oct 1999 A
5984957 Laptewicz, Jr. et al. Nov 1999 A
5997573 Quijano et al. Dec 1999 A
6022370 Tower Feb 2000 A
6027525 Suh et al. Feb 2000 A
6029671 Stevens et al. Feb 2000 A
6042589 Marianne Mar 2000 A
6042598 Tsugita et al. Mar 2000 A
6042607 Williamson, IV Mar 2000 A
6051014 Jang Apr 2000 A
6059809 Amor et al. May 2000 A
6110201 Quijano et al. Aug 2000 A
6146366 Schachar Nov 2000 A
6159239 Greenhalgh Dec 2000 A
6162208 Hipps Dec 2000 A
6162245 Jayaraman Dec 2000 A
6168614 Andersen et al. Jan 2001 B1
6171335 Wheatley et al. Jan 2001 B1
6200336 Pavcnik et al. Mar 2001 B1
6203550 Olson Mar 2001 B1
6210408 Chandrasekaran et al. Apr 2001 B1
6218662 Tchakarov et al. Apr 2001 B1
6221006 Dubrul et al. Apr 2001 B1
6221091 Khosravi Apr 2001 B1
6241757 An et al. Jun 2001 B1
6245102 Jayaraman Jun 2001 B1
6248116 Chevilon Jun 2001 B1
6258114 Konya et al. Jul 2001 B1
6258115 Dubrul Jul 2001 B1
6258120 McKenzie et al. Jul 2001 B1
6277555 Duran et al. Aug 2001 B1
6283127 Sterman Sep 2001 B1
6299637 Shaolia et al. Oct 2001 B1
6302906 Goicoechea et al. Oct 2001 B1
6309382 Garrison et al. Oct 2001 B1
6309417 Spence et al. Oct 2001 B1
6338735 Stevens Jan 2002 B1
6348063 Yassour et al. Feb 2002 B1
6350277 Kocur Feb 2002 B1
6352708 Duran et al. Mar 2002 B1
6371970 Khosravi et al. Apr 2002 B1
6371983 Lane Apr 2002 B1
6379383 Palmaz et al. Apr 2002 B1
6380457 Yurek et al. Apr 2002 B1
6398807 Chouinard et al. Jun 2002 B1
6409750 Hyodoh et al. Jun 2002 B1
6425916 Garrison et al. Jul 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6461382 Cao Oct 2002 B1
6468303 Amplatz et al. Oct 2002 B1
6475239 Campbell et al. Nov 2002 B1
6478806 McFarlane Nov 2002 B2
6482228 Norred Nov 2002 B1
6488704 Connelly et al. Dec 2002 B1
6494909 Greenhalgh Dec 2002 B2
6503272 Duerig et al. Jan 2003 B2
6508833 Pavcnik et al. Jan 2003 B2
6527800 McGuckin, Jr. et al. Mar 2003 B1
6530949 Konya et al. Mar 2003 B2
6530952 Vesely Mar 2003 B2
6562031 Chandrasekaran et al. May 2003 B2
6562058 Seguin et al. May 2003 B2
6569196 Vesely May 2003 B1
6582462 Andersen Jun 2003 B1
6585758 Chouinard et al. Jul 2003 B1
6592546 Barbut et al. Jul 2003 B1
6605112 Moll et al. Aug 2003 B1
6613063 Hunsberger Sep 2003 B1
6613077 Gilligan et al. Sep 2003 B2
6622604 Chouinard et al. Sep 2003 B1
6635068 Dubrul et al. Oct 2003 B1
6652571 White et al. Nov 2003 B1
6652578 Bailey et al. Nov 2003 B2
6656213 Solem Dec 2003 B2
6663663 Kim et al. Dec 2003 B2
6669724 Park et al. Dec 2003 B2
6673089 Yassour et al. Jan 2004 B1
6673109 Cox Jan 2004 B2
6676698 McGuckin, Jr. et al. Jan 2004 B2
6682558 Tu Jan 2004 B2
6682559 Myers Jan 2004 B2
6685724 Haluck Feb 2004 B1
6685739 DiMatteo et al. Feb 2004 B2
6689144 Gerberding Feb 2004 B2
6689164 Seguin Feb 2004 B1
6692512 Jang Feb 2004 B2
6692513 Streeter et al. Feb 2004 B2
6695878 McGuckin, Jr. et al. Feb 2004 B2
6702851 Chinn et al. Mar 2004 B1
6719787 Cox Apr 2004 B2
6719788 Cox Apr 2004 B2
6719789 Cox Apr 2004 B2
6730118 Spenser May 2004 B2
6730377 Wang May 2004 B2
6733525 Yang et al. May 2004 B2
6736846 Cox May 2004 B2
6752828 Thornton Jun 2004 B2
6758855 Fulton, III et al. Jul 2004 B2
6769434 Liddicoat et al. Aug 2004 B2
6786925 Schoon Sep 2004 B1
6790229 Berreklouw Sep 2004 B1
6792979 Konya et al. Sep 2004 B2
6797002 Spence Sep 2004 B2
6821297 Snyders Nov 2004 B2
6830575 Stenzel et al. Dec 2004 B2
6830584 Seguin Dec 2004 B1
6830585 Artof Dec 2004 B1
6846325 Liddicoat Jan 2005 B2
6866650 Stevens Mar 2005 B2
6872223 Roberts Mar 2005 B2
6875231 Anduiza et al. Apr 2005 B2
6883522 Spence et al. Apr 2005 B2
6887266 Williams et al. May 2005 B2
6890330 Streeter et al. May 2005 B2
6893460 Spenser May 2005 B2
6896690 Lambrecht et al. May 2005 B1
6908481 Cribier Jun 2005 B2
6913600 Valley et al. Jul 2005 B2
6929653 Streeter Aug 2005 B2
6936066 Palmaz et al. Aug 2005 B2
6939365 Fogarty et al. Sep 2005 B1
6951571 Srivastava Oct 2005 B1
6974474 Pavcnik et al. Dec 2005 B2
6974476 McGuckin et al. Dec 2005 B2
6986742 Hart et al. Jan 2006 B2
6989027 Allen et al. Jan 2006 B2
6989028 Lashinski et al. Jan 2006 B2
6991649 Sievers Jan 2006 B2
7018401 Hyodoh et al. Mar 2006 B1
7041128 McGuckin, Jr. et al. May 2006 B2
7044966 Svanidze et al. May 2006 B2
7048014 Hyodoh et al. May 2006 B2
7097659 Woolfson et al. Aug 2006 B2
7101396 Artof et al. Sep 2006 B2
7105016 Shui et al. Sep 2006 B2
7115141 Menz et al. Oct 2006 B2
7128759 Osborne et al. Oct 2006 B2
7147663 Berg et al. Dec 2006 B1
7153324 Case et al. Dec 2006 B2
7160319 Chouinard et al. Jan 2007 B2
7175656 Khairkhahan Feb 2007 B2
7186265 Sharkawy et al. Mar 2007 B2
7195641 Palmaz et al. Mar 2007 B2
7198646 Figulla et al. Apr 2007 B2
7201761 Woolfson et al. Apr 2007 B2
7201772 Schwammenthal et al. Apr 2007 B2
7252682 Seguin Aug 2007 B2
7300457 Palmaz Nov 2007 B2
7300463 Liddicoat Nov 2007 B2
7316706 Bloom et al. Jan 2008 B2
7329278 Seguin Feb 2008 B2
7335218 Wilson et al. Feb 2008 B2
7338520 Bailey et al. Mar 2008 B2
7374571 Pease et al. May 2008 B2
7377938 Sarac et al. May 2008 B2
7381218 Schreck Jun 2008 B2
7384411 Condado Jun 2008 B1
7429269 Schwammenthal et al. Sep 2008 B2
7442204 Schwammenthal et al. Oct 2008 B2
7462191 Spenser et al. Dec 2008 B2
7470284 Lambrecht et al. Dec 2008 B2
7481838 Carpentier et al. Jan 2009 B2
7544206 Cohn et al. Jun 2009 B2
7547322 Sarac et al. Jun 2009 B2
7556646 Yang et al. Jul 2009 B2
20010001314 Davison et al. May 2001 A1
20010002445 Vesely May 2001 A1
20010007956 Letac et al. Jul 2001 A1
20010010017 Letac et al. Jul 2001 A1
20010011189 Drasler et al. Aug 2001 A1
20010021872 Bailey et al. Sep 2001 A1
20010025196 Chinn et al. Sep 2001 A1
20010032013 Marton Oct 2001 A1
20010039450 Pavcnik et al. Nov 2001 A1
20010041928 Pavcnik et al. Nov 2001 A1
20010044647 Pinchuk et al. Nov 2001 A1
20020010508 Chobotov Jan 2002 A1
20020029014 Jayaraman Mar 2002 A1
20020032480 Spence et al. Mar 2002 A1
20020032481 Gabbay Mar 2002 A1
20020035396 Heath Mar 2002 A1
20020042650 Vardi et al. Apr 2002 A1
20020052651 Myers et al. May 2002 A1
20020058995 Stevens May 2002 A1
20020072789 Hackett et al. Jun 2002 A1
20020095209 Zadno-Azizi et al. Jul 2002 A1
20020099439 Schwartz et al. Jul 2002 A1
20020103533 Langberg et al. Aug 2002 A1
20020107565 Greenhalgh Aug 2002 A1
20020111674 Chouinard et al. Aug 2002 A1
20020123802 Snyders Sep 2002 A1
20020133183 Lentz et al. Sep 2002 A1
20020138138 Yang Sep 2002 A1
20020151970 Garrison et al. Oct 2002 A1
20020161392 Dubrul Oct 2002 A1
20020161394 Macoviak et al. Oct 2002 A1
20020193871 Beyersdorf et al. Dec 2002 A1
20030014104 Cribier Jan 2003 A1
20030023300 Bailey et al. Jan 2003 A1
20030023303 Palmaz et al. Jan 2003 A1
20030028247 Cali Feb 2003 A1
20030036791 Philipp et al. Feb 2003 A1
20030040771 Hyodoh et al. Feb 2003 A1
20030040772 Hyodoh et al. Feb 2003 A1
20030040792 Gabbay Feb 2003 A1
20030050694 Yang et al. Mar 2003 A1
20030055495 Pease et al. Mar 2003 A1
20030065386 Weadock Apr 2003 A1
20030069492 Abrams et al. Apr 2003 A1
20030109924 Cribier Jun 2003 A1
20030125795 Pavcnik et al. Jul 2003 A1
20030130726 Thorpe et al. Jul 2003 A1
20030130729 Paniagua et al. Jul 2003 A1
20030139804 Hankh et al. Jul 2003 A1
20030149475 Hyodoh et al. Aug 2003 A1
20030149476 Damm et al. Aug 2003 A1
20030149478 Figulla et al. Aug 2003 A1
20030153974 Spenser et al. Aug 2003 A1
20030181850 Diamond et al. Sep 2003 A1
20030191519 Lombardi et al. Oct 2003 A1
20030199913 Dubrul et al. Oct 2003 A1
20030199963 Tower et al. Oct 2003 A1
20030199971 Tower et al. Oct 2003 A1
20030212410 Stenzel et al. Nov 2003 A1
20030212454 Scott et al. Nov 2003 A1
20030225445 Derus et al. Dec 2003 A1
20040019374 Hojeibane et al. Jan 2004 A1
20040034411 Quijano et al. Feb 2004 A1
20040039436 Spenser et al. Feb 2004 A1
20040049224 Buehlmann et al. Mar 2004 A1
20040049262 Obermiller et al. Mar 2004 A1
20040049266 Anduiza et al. Mar 2004 A1
20040082904 Houde et al. Apr 2004 A1
20040088045 Cox May 2004 A1
20040092858 Wilson et al. May 2004 A1
20040092989 Wilson et al. May 2004 A1
20040093005 Durcan May 2004 A1
20040093060 Sequin et al. May 2004 A1
20040093075 Kuehn May 2004 A1
20040097788 Mourles et al. May 2004 A1
20040098112 DiMatteo et al. May 2004 A1
20040106976 Bailey et al. Jun 2004 A1
20040106990 Spence et al. Jun 2004 A1
20040111096 Tu et al. Jun 2004 A1
20040116951 Rosengart Jun 2004 A1
20040117004 Osborne et al. Jun 2004 A1
20040122468 Yodfat et al. Jun 2004 A1
20040122514 Fogarty et al. Jun 2004 A1
20040122516 Fogarty Jun 2004 A1
20040127979 Wilson Jul 2004 A1
20040138742 Myers et al. Jul 2004 A1
20040138743 Myers et al. Jul 2004 A1
20040153146 Lashinski et al. Aug 2004 A1
20040167573 Williamson Aug 2004 A1
20040167620 Ortiz Aug 2004 A1
20040186563 Iobbi Sep 2004 A1
20040193261 Berreklouw Sep 2004 A1
20040210240 Saint Oct 2004 A1
20040210304 Seguin et al. Oct 2004 A1
20040210307 Khairkhahan Oct 2004 A1
20040215333 Duran Oct 2004 A1
20040215339 Drasler et al. Oct 2004 A1
20040225353 McGuckin, Jr. Nov 2004 A1
20040225354 Allen Nov 2004 A1
20040225356 Frater Nov 2004 A1
20040254636 Flagle et al. Dec 2004 A1
20040260389 Case et al. Dec 2004 A1
20040260394 Douk et al. Dec 2004 A1
20040267357 Allen et al. Dec 2004 A1
20050010246 Streeter Jan 2005 A1
20050010285 Lambrecht et al. Jan 2005 A1
20050010287 Macoviak Jan 2005 A1
20050015112 Cohn et al. Jan 2005 A1
20050027348 Case et al. Feb 2005 A1
20050033398 Seguin Feb 2005 A1
20050043790 Seguin Feb 2005 A1
20050049692 Numamoto Mar 2005 A1
20050049696 Siess Mar 2005 A1
20050055088 Liddicoat et al. Mar 2005 A1
20050060029 Le Mar 2005 A1
20050060030 Lashinski et al. Mar 2005 A1
20050075584 Cali Apr 2005 A1
20050075712 Biancucci Apr 2005 A1
20050075717 Nguyen Apr 2005 A1
20050075719 Bergheim Apr 2005 A1
20050075724 Svanidze Apr 2005 A1
20050075727 Wheatley Apr 2005 A1
20050075730 Myers Apr 2005 A1
20050075731 Artof Apr 2005 A1
20050085841 Eversull et al. Apr 2005 A1
20050085842 Eversull et al. Apr 2005 A1
20050085843 Opolski et al. Apr 2005 A1
20050085890 Rasmussen et al. Apr 2005 A1
20050085900 Case et al. Apr 2005 A1
20050096568 Kato May 2005 A1
20050096692 Linder et al. May 2005 A1
20050096724 Stenzel et al. May 2005 A1
20050096734 Majercak et al. May 2005 A1
20050096735 Hojeibane et al. May 2005 A1
20050096736 Osse et al. May 2005 A1
20050096738 Cali et al. May 2005 A1
20050107871 Realyvasquez et al. May 2005 A1
20050113910 Paniagua May 2005 A1
20050119688 Berheim Jun 2005 A1
20050131438 Cohn Jun 2005 A1
20050137686 Salahieh Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137692 Haug Jun 2005 A1
20050137695 Salahieh Jun 2005 A1
20050137701 Salahieh Jun 2005 A1
20050143807 Pavcnik et al. Jun 2005 A1
20050143809 Salahieh Jun 2005 A1
20050148997 Valley et al. Jul 2005 A1
20050149181 Eberhardt Jul 2005 A1
20050165477 Anduiza et al. Jul 2005 A1
20050187616 Realyvasquez Aug 2005 A1
20050197695 Stacchino et al. Sep 2005 A1
20050203549 Realyvasquez Sep 2005 A1
20050203605 Dolan Sep 2005 A1
20050203618 Sharkawy Sep 2005 A1
20050222674 Paine Oct 2005 A1
20050228495 Macoviak Oct 2005 A1
20050234546 Nugent Oct 2005 A1
20050240200 Bergheim Oct 2005 A1
20050240263 Fogarty et al. Oct 2005 A1
20050261759 Lambrecht et al. Nov 2005 A1
20050283962 Boudjemline Dec 2005 A1
20060004439 Spenser et al. Jan 2006 A1
20060004469 Sokel Jan 2006 A1
20060009841 McGuckin et al. Jan 2006 A1
20060052867 Revuelta et al. Mar 2006 A1
20060058775 Stevens et al. Mar 2006 A1
20060089711 Dolan Apr 2006 A1
20060100685 Seguin et al. May 2006 A1
20060116757 Lashinski et al. Jun 2006 A1
20060135964 Vesely Jun 2006 A1
20060142848 Gabbay Jun 2006 A1
20060167474 Bloom et al. Jul 2006 A1
20060178740 Stacchino et al. Aug 2006 A1
20060195134 Crittenden Aug 2006 A1
20060206192 Tower et al. Sep 2006 A1
20060206202 Bonhoefer et al. Sep 2006 A1
20060212111 Case et al. Sep 2006 A1
20060247763 Slater Nov 2006 A1
20060259134 Schwammenthal et al. Nov 2006 A1
20060259136 Nguyen et al. Nov 2006 A1
20060259137 Artof et al. Nov 2006 A1
20060265056 Nguyen et al. Nov 2006 A1
20060271166 Thill et al. Nov 2006 A1
20060271175 Woolfson et al. Nov 2006 A1
20060276874 Wilson et al. Dec 2006 A1
20060276882 Case et al. Dec 2006 A1
20060282161 Huynh et al. Dec 2006 A1
20070005129 Damm et al. Jan 2007 A1
20070005131 Taylor Jan 2007 A1
20070010878 Raffiee et al. Jan 2007 A1
20070016286 Herrmann et al. Jan 2007 A1
20070027518 Case et al. Feb 2007 A1
20070027533 Douk Feb 2007 A1
20070038295 Case et al. Feb 2007 A1
20070043431 Melsheimer Feb 2007 A1
20070043435 Seguin et al. Feb 2007 A1
20070051377 Douk et al. Mar 2007 A1
20070073392 Heyninck-Janitz Mar 2007 A1
20070078509 Lotfy et al. Apr 2007 A1
20070078510 Ryan Apr 2007 A1
20070088431 Bourang et al. Apr 2007 A1
20070093869 Bloom et al. Apr 2007 A1
20070100439 Cangialosi May 2007 A1
20070100440 Figulla May 2007 A1
20070100449 O'Neil et al. May 2007 A1
20070112415 Bartlett May 2007 A1
20070162102 Ryan et al. Jul 2007 A1
20070162113 Sharkawy et al. Jul 2007 A1
20070185513 Woolfson et al. Aug 2007 A1
20070203391 Bloom et al. Aug 2007 A1
20070225681 House Sep 2007 A1
20070232898 Huynh et al. Oct 2007 A1
20070233228 Eberhardt et al. Oct 2007 A1
20070233237 Krivoruchko Oct 2007 A1
20070233238 Huynh et al. Oct 2007 A1
20070238979 Huynh et al. Oct 2007 A1
20070239254 Marchand et al. Oct 2007 A1
20070239265 Birdsall Oct 2007 A1
20070239266 Birdsall Oct 2007 A1
20070239269 Dolan et al. Oct 2007 A1
20070239273 Allen Oct 2007 A1
20070244544 Birdsall et al. Oct 2007 A1
20070244545 Birdsall et al. Oct 2007 A1
20070244546 Francis Oct 2007 A1
20070244553 Rafiee et al. Oct 2007 A1
20070244554 Rafiee et al. Oct 2007 A1
20070244555 Rafiee et al. Oct 2007 A1
20070244556 Rafiee et al. Oct 2007 A1
20070244557 Rafiee et al. Oct 2007 A1
20070250160 Rafiee Oct 2007 A1
20070255394 Ryan Nov 2007 A1
20070255396 Douk et al. Nov 2007 A1
20070288000 Bonan Dec 2007 A1
20080004696 Vesely Jan 2008 A1
20080009940 Cribier Jan 2008 A1
20080015671 Bonhoeffer Jan 2008 A1
20080021552 Gabbay Jan 2008 A1
20080048656 Tan Feb 2008 A1
20080065011 Marchand et al. Mar 2008 A1
20080065206 Liddicoat Mar 2008 A1
20080071361 Tuval et al. Mar 2008 A1
20080071362 Tuval et al. Mar 2008 A1
20080071363 Tuval et al. Mar 2008 A1
20080071366 Tuval et al. Mar 2008 A1
20080071368 Tuval et al. Mar 2008 A1
20080077234 Styrc Mar 2008 A1
20080082165 Wilson et al. Apr 2008 A1
20080082166 Styrc et al. Apr 2008 A1
20080133003 Seguin et al. Jun 2008 A1
20080140189 Nguyen et al. Jun 2008 A1
20080147105 Wilson et al. Jun 2008 A1
20080147180 Ghione et al. Jun 2008 A1
20080147181 Ghione et al. Jun 2008 A1
20080147182 Righini et al. Jun 2008 A1
20080154355 Benichow et al. Jun 2008 A1
20080154356 Obermiller et al. Jun 2008 A1
20080161910 Revuelta et al. Jul 2008 A1
20080161911 Revuelta et al. Jul 2008 A1
20080183273 Mesana et al. Jul 2008 A1
20080188928 Salahieh et al. Aug 2008 A1
20080215143 Seguin et al. Sep 2008 A1
20080215144 Ryan et al. Sep 2008 A1
20080228254 Ryan Sep 2008 A1
20080228263 Ryan Sep 2008 A1
20080234797 Styrc Sep 2008 A1
20080243246 Ryan et al. Oct 2008 A1
20080255651 Dwork Oct 2008 A1
20080255660 Guyenot et al. Oct 2008 A1
20080255661 Straubinger et al. Oct 2008 A1
20080262593 Ryan et al. Oct 2008 A1
20080269878 Iobbi Oct 2008 A1
20090005863 Goetz et al. Jan 2009 A1
20090012600 Styrc et al. Jan 2009 A1
20090048656 Wen Feb 2009 A1
20090054976 Tuval et al. Feb 2009 A1
20090069886 Suri et al. Mar 2009 A1
20090069887 Righini et al. Mar 2009 A1
20090069889 Suri et al. Mar 2009 A1
20090085900 Weiner Apr 2009 A1
20090099653 Suri et al. Apr 2009 A1
20090138079 Tuval et al. May 2009 A1
20090164004 Cohn Jun 2009 A1
20090171447 VonSeggesser et al. Jul 2009 A1
20090192585 Bloom et al. Jul 2009 A1
20090192586 Tabor et al. Jul 2009 A1
20090192591 Ryan et al. Jul 2009 A1
20090198316 Laske et al. Aug 2009 A1
20090216310 Straubinger et al. Aug 2009 A1
20090216312 Straubinger et al. Aug 2009 A1
20090216313 Straubinger et al. Aug 2009 A1
20090234443 Ottma et al. Sep 2009 A1
20090240264 Tuval et al. Sep 2009 A1
20090240320 Tuval Sep 2009 A1
20090287296 Manasse Nov 2009 A1
20100036479 Hill et al. Feb 2010 A1
20100094411 Tuval et al. Apr 2010 A1
20100100167 Bortlein et al. Apr 2010 A1
20100131054 Tuval et al. May 2010 A1
20100137979 Tuval et al. Jun 2010 A1
20100161045 Righini Jun 2010 A1
20100234940 Dolan Sep 2010 A1
Foreign Referenced Citations (48)
Number Date Country
2007-100074433 Aug 2007 CN
3640745 Jun 1987 DE
195 32 846 Mar 1997 DE
195 46 692 Jun 1997 DE
195 46 692 Jun 1997 DE
198 57 887 Jul 2000 DE
199 07 646 Aug 2000 DE
100 49 812 Apr 2002 DE
100 49 813 Apr 2002 DE
100 49 815 Apr 2002 DE
1057460 Jun 2000 EP
1255510 Nov 2002 EP
1469797 Nov 2005 EP
2788217 Dec 1999 FR
2815844 May 2000 FR
2056023 Mar 1981 GB
2433700 Dec 2007 GB
1271508 Nov 1986 SU
9529640 Nov 1995 WO
WO 00-12032 Mar 2000 WO
0047136 Aug 2000 WO
0135870 May 2001 WO
0149213 Jul 2001 WO
0154625 Aug 2001 WO
0162189 Aug 2001 WO
0164137 Sep 2001 WO
0222054 Mar 2002 WO
0236048 May 2002 WO
WO 02-49546 Jun 2002 WO
03003943 Jan 2003 WO
03003949 Jan 2003 WO
03011195 Feb 2003 WO
WO 03-047468 Jun 2003 WO
2004019825 Mar 2004 WO
2004089250 Oct 2004 WO
2005004753 Jan 2005 WO
WO 2005-046528 May 2005 WO
2006026371 Mar 2006 WO
2008047354 Apr 2008 WO
2008138584 Nov 2008 WO
2008150529 Dec 2008 WO
2009002548 Dec 2008 WO
2009029199 Mar 2009 WO
2009042196 Apr 2009 WO
2009045338 Apr 2009 WO
2009061389 May 2009 WO
2009091509 Jul 2009 WO
2009111241 Sep 2009 WO
Non-Patent Literature Citations (66)
Entry
Andersen, H.R. et al, “Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs.” Euro. Heart J. (1992) 13:704-708.
Babaliaros, et al., “State of the Art Percutaneous Intervention for the Treatment of Valvular Heart Disease: A Review of the Current Technologies and Ongoing Research in the Field of Percutaneous Heart Valve Replacement and Repair,” Cardiology 2007; 107:87-96.
Bailey, “Percutaneous Expandable Prosthetic Valves,” in: Topol EJ, ed. Textbook of Interventional Cardiology. Volume II. Second edition. WB Saunders, Philadelphia, 1994:1268-1276.
Block, et al., “Percutaneous Approaches to Valvular Heart Disease,” Current Cardiology Reports, vol. 7 (2005) pp. 108-113.
Bonhoeffer, et al, “Percutaneous Insertion of the Pulmonary Valve,” Journal of the American College of Cardiology (United States), May 15, 2002, pp. 1664-1669.
Bonhoeffer, et al, “Percutaneous Replacement of Pulmonary Valve in a Right-Ventricle to Pulmonary-Artery Prosthetic Conduit with Valve Dysfunction,” Lancet (England), Oct. 21, 2000, pp. 1403-1405.
Bonhoeffer, et al, “Transcatheter Implantation of a Bovine Valve in Pulmonary Position: A Lamb Study,” Circulation (United States), Aug. 15, 2000, pp. 813-816.
Boudjemline, et al, “Images in Cardiovascular Medicine. Percutaneous Aortic Valve Replacement in Animals,” Circulation (United States), Mar. 16, 2004, 109, p. e161.
Boudjemline, et al, “Is Percutaneous Implantation of a Bovine Venous Valve in the Inferior Vena Cava a Reliable Technique to Treat Chronic Venous Insufficiency Syndrome?” Medical Science Monitor—International Medical Journal of Experimental and Clinical Research (Poland), Mar. 2004, pp. BR61-BR66.
Boudjemline, et al, “Off-pump Replacement of the Pulmonary Valve in Large Right Ventricular Outflow Tracts: A Hybrid Approach,” Journal of Thoracic and Cardiovascular Surgery (United States), Apr. 2005, pp. 831-837.
Boudjemline, et al, “Percutaneous Aortic Valve Replacement: Will We Get There?” Heart (British Cardiac Society) (England), Dec. 2001, pp. 705-706.
Boudjemline, et al, “Percutaneous Implantation of a Biological Valve in the Aorta to Treat Aortic Valve Insufficiency—A Sheep Study,” Medical Science Monitor—International Medical Journal of Experimental and Clinical Research (Poland), Apr. 2002, pp. BR113-BR116.
Boudjemline, et al, “Percutaneous Implantation of a Biological Valve in Aortic Position: Preliminary Results in a Sheep Study,” European Heart Journal 22, Sep. 2001, p. 630.
Boudjemline, et al, “Percutaneous Implantation of a Valve in the Descending Aorta in Lambs,” European Heart Journal (England), Jul. 2002, pp. 1045-1049.
Boudjemline, et al, “Percutaneous Pulmonary Valve Replacement in a Large Right Ventricular Outflow Tract: An Experimental Study,” Journal of the American College of Cardiology (United States), Mar. 17, 2004, pp. 1082-1087.
Boudjemline, et al, “Percutaneous Valve Insertion: A New Approach,” Journal of Thoracic and Cardiovascular Surgery (United States), Mar. 2003, pp. 741-742.
Boudjemline, et al, “Stent Implantation Combined with a Valve Replacement to Treat Degenerated Right Ventricle to Pulmonary Artery Prosthetic Conduits,” European Heart Journal 22, Sep. 2001, p. 355.
Boudjemline, et al, “Steps Toward Percutaneous Aortic Valve Replacement,” Circulation (United States), Feb. 12, 2002, pp. 775-778.
Boudjemline, et al, “The Percutaneous Implantable Heart Valve,” Progress in Pediatric Cardiology (Ireland), 2001, pp. 89-93.
Boudjemline, et al, “Transcatheter Reconstruction of the Right Heart,” Cardiology in the Young (England), Jun. 2003, pp. 308-311.
Coats, et al, “The Potential Impact of Percutaneous Pulmonary Valve Stent Implantation on Right Ventricular Outflow Tract Re-Intervention,” European Journal of Cardio-Thoracic Surgery (England), Apr. 2005, pp. 536-543.
Cribier, A. et al, “Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case Description,” Circulation (2002) 3006-3008.
Davidson et al., “Percutaneous therapies for valvular heart disease,” Cardiovascular Pathology 15 (2006) 123-129.
Hanzel, et al., “Complications of percutaneous aortic valve replacement: experience with the Criber-Edwards™ percutaneous heart valve,” EuroIntervention Supplements (2006), 1 (Supplement A) A3-A8.
Huber, et al., “Do Valved Stents Compromise Coronary Flow?” Eur. J. Cardiothorac. Surg. 2004;25:754-759.
Khambadkone, “Nonsurgical Pulmonary Valve Replacement: Why, When, and How?” Catheterization and Cardiovascular Interventions—Official Journal of the Society for Cardiac Angiography & Interventions (United States), Jul. 2004, pp. 401-408.
Khambadkone, et al, “Percutaneous Implantation of Pulmonary Valves,” Expert Review of Cardiovascular Therapy (England), Nov. 2003, pp. 541-548.
Khambadkone, et al, “Percutaneous Pulmonary Valve Implantation: Early and Medium Term Results,” Circulation 108 (17 Supplement), Oct. 28, 2003, p. IV-375.
Khambadkone, et al, “Percutaneous Pulmonary Valve Implantation: Impact of Morphology on Case Selection,” Circulation 108 (17 Supplement), Oct. 28, 2003, p. IV-642-IV-643.
Lutter, et al, “Percutaneous Aortic Valve Replacement: An Experimental Study. I. Studies on Implantation,” The Journal of Thoracic and Cardiovascular Surgery, Apr. 2002, pp. 768-776.
Lutter, et al, “Percutaneous Valve Replacement: Current State and Future Prospects,” Annals of Thoracic Surgery (Netherlands), Dec. 2004, pp. 2199-2206.
Medtech Insight, “New Frontiers in Heart Valve Disease,” vol. 7, No. 8 (2005).
Palacios, “Percutaneous Valve Replacement and Repair, Fiction or Reality?” Journal of American College of Cardiology, vol. 44, No. 8 (2004) pp. 1662-1663.
Pelton et al., “Medical Uses of Nitinol,” Materials Science Forum vols. 327-328, pp. 63-70 (2000).
Ruiz, “Transcathether Aortic Valve Implantation and Mitral Valve Repair: State of the Art,” Pediatric Cardiology, vol. 26, No. 3 (2005).
Saliba, et al, “Treatment of Obstructions of Prosthetic Conduits by Percutaneous Implantation of Stents,” Archives des Maldies du Coeur et des Vaisseaux (France), 1999, pp. 591-596.
Webb, et al., “Percutaneous Aortic Valve Implantation Retrograde from the Femoral Artery,” Circulation (2006), 113;842-850.
Stassano et al., “Mid-term results of the valve-on-valve technique for bioprosthetic failure,” Eur. J. Cardiothorac. Surg. 2000; 18:453-457.
Expert report of Dr. Nigel Buller, dated Jan. 12, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (83 pages).
Expert report of Dr. Nigel Buller, non-confidential annex—infringement, dated Jan. 12, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (12 pages).
Expert report of Dr. Rodolfo Quijano, dated Jan. 9, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (18 pages).
First Expert report of Prof. David Williams, dated Jan. 12, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (41 pages).
First Expert report of Prof. Martin Rothman, dated Jan. 12, 2009, Edwards Lifesciences and Cook Biotech, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (64 pages).
Fourth Expert report of Prof. Martin Rothman, dated Apr. 22, 2009, Edwards Lifesciences and Cook Biotech, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (10 pages).
Second Expert report of Dr. Nigel Buller, dated Feb. 25, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (24 pages).
Second Expert report of Dr. Rodolfo Quijano, dated Feb. 26, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (6 pages).
Second Expert report of Prof. David Williams, dated Feb. 5, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (15 pages).
Second Expert report of Prof. Martin Rothman, dated Feb. 5, 2009, Edwards Lifesciences and Cook Biotech, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (11 pages).
Third Expert report of Dr. Nigel Buller, dated Apr. 21, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (6 pages).
Third Expert report of Dr. Rudolfo Quijano, dated Apr. 27, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (3 pages).
Third Expert report of Prof. David Williams, dated Apr. 22, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (9 pages).
Pavcnik et al., “Aortic and venous valve for percutaneous insertion,” Min. Invas. Ther. & Allied Techol. 2000, vol. 9, pp. 287-292.
First Expert report of Dr. Nigel Person Buller (30 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243.
Second Expert report of Dr. Nigel Person Buller (5 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243.
Drawing by Dr. Buller (Edwards Expert) of “higher stent” on the schematic representation of the aortic valve area set out in Figure 2 of Rothman's first expert report (1 page), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243.
First Expert report of Professor John R. Pepper (20 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243.
Second Expert report of Professor John R. Pepper (3 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243.
First Expert report of Dr. Anthony C. Lunn (7 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243.
First Witness statement of Stanton Rowe (9 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243.
Second Witness statement of Stanton Rowe (3 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243.
PVT slides naming Alain Cribier, Martin Leon, Stan Rabinovich and Stanton Rowe (16 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243.
Expert Rebuttal Report of Prof. Martin T. Rothman (32 pages) redacted, Edwards v. Core Valve, U.S. District Court, District of Delaware, Case No. 08-091, dated Jul. 29, 2009.
Expert Report of Prof. Martin T. Rothman (74 pages) redacted, Edwards v. CoreValve, U.S. District Court, District of Delaware, Case No. 08-091, dated Jun. 29, 2009.
First Expert report of Richard A. Hillstead (41 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243.
Reply Expert report of Richard A. Hillstead (9 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243.
Drawing by Dr. Buller (Edwards Expert) of his interpretation of the “higher stent” referred to at col. 8, lines 13-222 of Andersen EP 592410B1 (1 page), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243.
Related Publications (1)
Number Date Country
20070270944 A1 Nov 2007 US
Provisional Applications (1)
Number Date Country
60565118 Apr 2004 US
Continuations (1)
Number Date Country
Parent 11112757 Apr 2005 US
Child 11685025 US